A mediator of phosphorylated Smad2/3, evodiamine, in the reversion of TAF-induced EMT in normal colonic epithelial cells

Wan-bin, Yang; Gong, Xiaohua; Wang, Xiulian; Huang, Chao

doi:10.1007/s10637-018-0702-x

Cited by 14 publications

(7 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, EVO suppresses cancer growing by eliminating stemness and inhibiting invasion and migration (7,31). This is mainly due to the downregulation of epithelial-mesenchymal transition (EMT) (32)(33)(34). For instance, EVO elevated epithelial marker E-cadherin and reduced the expression of mesenchymal markers N-cadherin and vimentin (33), as well as matrix metalloproteinase-2 (MMP-2) and matrix metalloproteinase-9 (MMP-9) protein levels (32).…”

Section: Discussionmentioning

confidence: 99%

Antitumor Effects of Evodiamine in Mice Model Experiments: A Systematic Review and Meta-Analysis

et al. 2021

View full text Add to dashboard Cite

BackgroundEvodiamine (EVO), an alkaloid extracted from the traditional Chinese medicine Euodia rutaecarpa, plays an important role in the treatment of cancer. This study was performed to clarify the effects of evodiamine in mice tumor model studies.MethodsElectronic databases and search engines involved China Knowledge Resource Integrated Database (CNKI), Wanfang Database, Chinese Scientific Journal Database (CSJD-VIP), China Biomedical Literature Database (CBM), PubMed, Embase, Web of Science, and ClinicalTrials.gov databases, which were searched for literature related to the antitumor effects of evodiamine in animal tumor models (all until 1 October 2021). The evodiamine effects on the tumor volume and tumor weight were compared between the treatment and control groups using the standardized mean difference (SMD).ResultsEvodiamine significantly inhibited tumor growth in mice, as was assessed with tumor volume [13 studies, n=267; 138 for EVO and 129 for control; standard mean difference (SMD)= -5.99; 95% (CI): -8.89 to -3.10; I2 = 97.69%, p ≤ 0.00], tumor weight [6 studies, n=89; 49 for EVO and 40 for control; standard mean difference (SMD)= -3.51; 95% (CI): -5.13 to -3.90; I2 = 83.02%, p ≤ 0.00].ConclusionEVO significantly suppresses tumor growth in mice models, which would be beneficial for clinical transformation. However, due to the small number of studies included in this meta-analysis, the experimental design and experimental method limitations should be considered when interpreting the results. Significant clinical and animal studies are still required to evaluate whether EVO can be used in the adjuvant treatment of clinical tumor patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Antitumor Effects of Evodiamine in Mice Model Experiments: A Systematic Review and Meta-Analysis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Detection of immunofluorescence for E-cadherin, vimentin and α-SMA in HCoEpiC cells was performed as previously described (Yang et al 2018). Briefly, the HCoEpiCs treated with different conditions were washed, fixed, and permeabilized.…”

Section: Immunofluorescence (If) Stainingmentioning

confidence: 99%

“…HCoEpiC, a human normal colonic epithelial cell line from American Type Culture Collection (ATCC), was purchased GuangZhou Jennio Biotech Co., Ltd. (China), and CCD-18Co cells, a human colonic myofibroblast line, were obtained from ATCC. HCoEpiC cells and CCD-18Co cells were recovered and cultured as previously described (Yang et al 2018).…”

Section: Cell Line Origin and Maintenancementioning

confidence: 99%

“…The p38 MAPK inhibitor VX-702 was also employed (SD5960, Beyotime, China). All primary antibodies, including E-cadherin, vimentin, α-SMA, ZEB1, Snail, Smad2/p-Smad2, Smad3/p-Smad3 and Smad4, as well as secondary antibodies, were previously described (Yang et al 2018). In addition, mouse monoclonal anti-phospho-p38 MAPK antibody (AM063, Beyotime), mouse monoclonal anti-p38 MAPK antibody (AM065, Beyotime), mouse monoclonal anti-Bax antibody (AB026, Beyotime) and rabbit monoclonal anti-Bcl-2 antibody (AB112, Beyotime) were also included.…”

Section: Primary Antibodies and Reagentsmentioning

confidence: 99%

See 1 more Smart Citation

Berberine inhibits epithelial-mesenchymal transition and promotes apoptosis of tumour-associated fibroblast-induced colonic epithelial cells through regulation of TGF-β signalling

Huang

Wang²,

Qi³

et al. 2019

J. Cell Commun. Signal.

Self Cite

View full text Add to dashboard Cite

Tumour-associated fibroblasts (TAFs) mediate the differentiation of adjacent stromal cells. Berberine (BBR), a monomer of traditional Chinese herbs, exhibits a potent therapeutic effect against cancer. However, the effects of BBR on the differentiation of normal colonic epithelial cells induced by TAFs have not been determined. In the present study, we selected the TAF-like myofibroblast cell line CCD-18Co. CCD-18Co-derived conditioned medium (CM) and co-culture induced epithelialmesenchymal transition (EMT) changes in colonic epithelial HCoEpiC cells with decreased E-cadherin and increased vimentin and α-SMA expression. In addition, CCD-18Co stimulated the expression of ZEB1 and Snail and promoted motility. We used LY364947, a TGF-β receptor kinase type I (TβRI) inhibitor, and BBR. Our results showed that LY364947 and BBR inhibited these phenomena. BBR decreased the expression of ZEB1 and Snail, and this effect was concentration dependent. BBR also downregulated the expression of TβRI, TβRII, Smad2/p-Smad2 and Smad3/p-Smad3. In addition, BBR induced apoptosis in EMT-like HCoEpiC cells in a concentration-dependent manner with upregulation of Bax and downregulation of Bcl-2. However, VX-702, an inhibitor of p38 MAPK, significantly suppressed the apoptosis rate. BBR promoted the expression of p38 MAPK and phosphorylated p38 MAPK. In conclusion, berberine inhibits EMT and promotes apoptosis in TAF-induced colonic epithelial cells through mediation of the Smad-dependent and SMAD-independent TGF-β signalling pathways.

show abstract

“…Evodiamine has also been recognized as a multi-target drug because it has evolved a prominent ability to bind various proteins (13). Yang et al reported that evodiamine can act as an TRPV1 agonist in the reversion of tumor-associated fibroblast (TAF)-induced epithelial-mesenchymal transition (EMT) in normal colonic epithelial cells (15). In the present study, evodiamine was used as a TRPV1 agonist to study and confirm the inhibitory mechanism of diosmetin (DIO) on osteoporosis.…”

Section: Introductionmentioning

confidence: 99%

Diosmetin reduces bone loss and osteoclastogenesis by regulating the expression of TRPV1 in osteoporosis rats

Huang

Chen

et al. 2020

Ann Transl Med

View full text Add to dashboard Cite

Background: Osteoporosis is a systemic skeletal disorder and occurs frequently in postmenopausal women and older men. This study aimed to examine whether diosmetin (DIO) can relieve estrogen deficiencyinduced osteoporosis and to explore the underlying mechanisms of this potential effect.Methods: Forty-nine Sprague-Dawley (SD) rats were divided into seven groups. Six groups underwent bilateral ovariectomy (OVX), while the sham group underwent ovarian exposure surgery. DIO and evodiamine were administered 3 days before surgery, and then subcutaneously every 3 days for 3 months in the following fashion: group I, DIO (100 mg/kg); group II, OVX; group III, OVX + DIO (50 mg/kg); group IV, OVX + DIO (100 mg/kg); group V, OVX + evodiamine (10 mg/kg) group; group VI, OVX + DIO (100 mg/kg) + evodiamine (10 mg/kg) group. Bone histopathological damage, bone loss, osteoclast production, and the expression level of transient receptor potential vanilloid 1 (TRPV1) were detected.Results: Compared with the sham group, the expression of bone resorption-related genes, osteoclastassociated receptor (OSCAR) (1.00%±0.16% versus 4.5%±0.28%, **, P<0.01) and tartrate-resistant acid phosphatase (TRAP) (2.0%±0.6% versus 18.00±1.2%, ***, P<0.001), was increased significantly. The protein level of osteogenic marker proteins, osterix (Osx) (1.0%±0.1% versus 0.03%±0.01%, **, P<0.01) and type 1 collagen (COL1A1) (1.0%±0.13% versus 0.13%±0.05%, **, P<0.01) was decreased significantly with the increase of TRPV1 (1.0%±0.15% versus 2.89%±0.28%, **, P<0.01) protein level. Notably, DIO can alleviate some abnormal symptoms related to osteoporosis.Conclusions: DIO can relieve typical osteoporosis symptoms in an OVX osteoporosis rat model. The underlying mechanism may be associated with the downregulation of TRPV1.

show abstract

A mediator of phosphorylated Smad2/3, evodiamine, in the reversion of TAF-induced EMT in normal colonic epithelial cells

Cited by 14 publications

References 37 publications

Antitumor Effects of Evodiamine in Mice Model Experiments: A Systematic Review and Meta-Analysis

Antitumor Effects of Evodiamine in Mice Model Experiments: A Systematic Review and Meta-Analysis

Berberine inhibits epithelial-mesenchymal transition and promotes apoptosis of tumour-associated fibroblast-induced colonic epithelial cells through regulation of TGF-β signalling

Diosmetin reduces bone loss and osteoclastogenesis by regulating the expression of TRPV1 in osteoporosis rats

Contact Info

Product

Resources

About